vs

Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $18.7M, roughly 1.0× AMES NATIONAL CORP). AMES NATIONAL CORP runs the higher net margin — 34.9% vs -177.4%, a 212.3% gap on every dollar of revenue. On growth, AMES NATIONAL CORP posted the faster year-over-year revenue change (26.7% vs -11.5%). AMES NATIONAL CORP produced more free cash flow last quarter ($20.7M vs $-23.1M). Over the past eight quarters, AMES NATIONAL CORP's revenue compounded faster (19.5% CAGR vs -12.2%).

Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

ATLO vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.0× larger
LAB
$19.6M
$18.7M
ATLO
Growing faster (revenue YoY)
ATLO
ATLO
+38.1% gap
ATLO
26.7%
-11.5%
LAB
Higher net margin
ATLO
ATLO
212.3% more per $
ATLO
34.9%
-177.4%
LAB
More free cash flow
ATLO
ATLO
$43.8M more FCF
ATLO
$20.7M
$-23.1M
LAB
Faster 2-yr revenue CAGR
ATLO
ATLO
Annualised
ATLO
19.5%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ATLO
ATLO
LAB
LAB
Revenue
$18.7M
$19.6M
Net Profit
$6.5M
$-34.7M
Gross Margin
48.5%
Operating Margin
44.3%
-168.5%
Net Margin
34.9%
-177.4%
Revenue YoY
26.7%
-11.5%
Net Profit YoY
85.4%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLO
ATLO
LAB
LAB
Q4 25
$18.7M
Q3 25
$16.6M
$19.6M
Q2 25
$16.1M
$21.8M
Q1 25
$15.5M
$40.8M
Q4 24
$14.7M
Q3 24
$13.5M
$22.1M
Q2 24
$13.5M
$22.5M
Q1 24
$13.1M
$45.5M
Net Profit
ATLO
ATLO
LAB
LAB
Q4 25
$6.5M
Q3 25
$4.6M
$-34.7M
Q2 25
$4.5M
$-33.5M
Q1 25
$3.4M
$-26.0M
Q4 24
$3.5M
Q3 24
$2.2M
$-26.9M
Q2 24
$2.2M
$-45.7M
Q1 24
$2.3M
$-32.2M
Gross Margin
ATLO
ATLO
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
ATLO
ATLO
LAB
LAB
Q4 25
44.3%
Q3 25
34.5%
-168.5%
Q2 25
35.0%
-118.1%
Q1 25
27.4%
-80.8%
Q4 24
29.4%
Q3 24
19.4%
-120.9%
Q2 24
19.0%
-134.5%
Q1 24
20.8%
-132.2%
Net Margin
ATLO
ATLO
LAB
LAB
Q4 25
34.9%
Q3 25
27.5%
-177.4%
Q2 25
28.0%
-153.7%
Q1 25
22.3%
-63.8%
Q4 24
23.8%
Q3 24
16.4%
-122.0%
Q2 24
16.2%
-203.3%
Q1 24
17.6%
-70.6%
EPS (diluted)
ATLO
ATLO
LAB
LAB
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLO
ATLO
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$126.8M
$129.4M
Total DebtLower is stronger
$18.4M
Stockholders' EquityBook value
$207.9M
$399.7M
Total Assets
$2.1B
$539.6M
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLO
ATLO
LAB
LAB
Q4 25
$126.8M
Q3 25
$108.2M
$129.4M
Q2 25
$95.2M
$158.6M
Q1 25
$163.4M
$150.9M
Q4 24
$101.2M
Q3 24
$59.0M
$210.6M
Q2 24
$63.4M
$269.8M
Q1 24
$111.4M
$287.1M
Total Debt
ATLO
ATLO
LAB
LAB
Q4 25
$18.4M
Q3 25
Q2 25
Q1 25
Q4 24
$20.0M
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
ATLO
ATLO
LAB
LAB
Q4 25
$207.9M
Q3 25
$200.6M
$399.7M
Q2 25
$193.0M
$424.5M
Q1 25
$183.1M
$454.6M
Q4 24
$174.7M
Q3 24
$183.4M
$489.3M
Q2 24
$167.1M
$510.3M
Q1 24
$165.5M
$577.3M
Total Assets
ATLO
ATLO
LAB
LAB
Q4 25
$2.1B
Q3 25
$2.1B
$539.6M
Q2 25
$2.1B
$557.0M
Q1 25
$2.2B
$579.6M
Q4 24
$2.1B
Q3 24
$2.1B
$681.5M
Q2 24
$2.1B
$708.7M
Q1 24
$2.2B
$777.7M
Debt / Equity
ATLO
ATLO
LAB
LAB
Q4 25
0.09×
Q3 25
Q2 25
Q1 25
Q4 24
0.11×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLO
ATLO
LAB
LAB
Operating Cash FlowLast quarter
$21.3M
$-22.2M
Free Cash FlowOCF − Capex
$20.7M
$-23.1M
FCF MarginFCF / Revenue
110.8%
-118.1%
Capex IntensityCapex / Revenue
3.4%
4.5%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$34.2M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLO
ATLO
LAB
LAB
Q4 25
$21.3M
Q3 25
$2.8M
$-22.2M
Q2 25
$4.0M
$-20.7M
Q1 25
$7.1M
$-30.3M
Q4 24
$14.3M
Q3 24
$3.1M
$-27.9M
Q2 24
$3.9M
$-39.0M
Q1 24
$1.4M
$-62.5M
Free Cash Flow
ATLO
ATLO
LAB
LAB
Q4 25
$20.7M
Q3 25
$2.6M
$-23.1M
Q2 25
$3.9M
$-22.6M
Q1 25
$6.9M
$-35.3M
Q4 24
$14.0M
Q3 24
$3.0M
$-30.1M
Q2 24
$3.8M
$-41.0M
Q1 24
$1.3M
$-63.3M
FCF Margin
ATLO
ATLO
LAB
LAB
Q4 25
110.8%
Q3 25
16.0%
-118.1%
Q2 25
24.2%
-103.6%
Q1 25
44.8%
-86.6%
Q4 24
94.9%
Q3 24
22.5%
-136.4%
Q2 24
28.1%
-182.2%
Q1 24
10.0%
-138.9%
Capex Intensity
ATLO
ATLO
LAB
LAB
Q4 25
3.4%
Q3 25
0.6%
4.5%
Q2 25
0.7%
8.7%
Q1 25
1.3%
12.4%
Q4 24
2.0%
Q3 24
0.5%
10.2%
Q2 24
0.7%
8.6%
Q1 24
0.5%
1.7%
Cash Conversion
ATLO
ATLO
LAB
LAB
Q4 25
3.28×
Q3 25
0.60×
Q2 25
0.89×
Q1 25
2.07×
Q4 24
4.07×
Q3 24
1.40×
Q2 24
1.78×
Q1 24
0.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATLO
ATLO

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons